BAG3 Dilated Cardiomyopathy Natural History Study
Part of Genetic & congenital, Heart & circulation clinical trials.
This study follows people with a specific genetic change in the BAG3 gene that causes dilated cardiomyopathy (DCM), a condition where the heart muscle is weakened. It aims to understand the natural course of the disease over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with dilated cardiomyopathy with mild to moderate heart weakness.
- A genetic test has confirmed you have a harmful change in the BAG3 gene.
- Your heart failure symptoms are mild to moderate (NYHA class I, II, or III).
- You are not currently using a mechanical heart pump or have had a heart transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy called RP-A701 for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The goal is to see if it is safe and can improve heart function.
This trial tests a gene therapy (AFTX-201) for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The therapy aims to improve heart function, and the study will check if it is safe and effective.
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
This study looks at how small blood vessels in the heart affect outcomes in people with dilated cardiomyopathy (an enlarged, weak heart). You may qualify if you have heart failure with a weak pump and no significant blockages in your main heart arteries.
This study offers genetic testing to adults with a type of heart muscle disease (non-ischemic cardiomyopathy or dilated cardiomyopathy) that is not caused by blocked arteries. The goal is to find genetic causes, which may guide treatment and family screening.
This study is a registry for people with dilated cardiomyopathy (DCM)—a condition where the heart's main pumping chamber becomes enlarged and weak. It aims to learn more about DCM, especially in people from different ethnic backgrounds, by collecting health information over time.
Hear when a new Dilated Cardiomyopathy (DCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.